BRAF and melanoma: In any case, these unexpected findings hinted at the possibility that the eIF4F action in the control of the oncogenic MAPK signaling in human melanoma might not be limited to the context of cellular resistance to BRAF and MEK inhibitors, warranting further studies in treatment-naïve melanoma cells.